Despite Investors Doubts, AGTC Founder SaysBioinformaticsisStillaSafeBet | GenomeWeb

David Stone, a founding partner with Applied Genomic Technology Capital Funds, said he hasn’t lost his enthusiasm for the burgeoning bioinformatics sector, despite indications that investment in new genomics and bioinformatics companies may continue to slow in the coming year.

Although analysts such as Rob Olan at JP Morgan H&Q have cautioned that the bioinformatics and genomics investment atmosphere would be “less euphoric” in 2001, Stone doesn’t see this as cause for concern.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.